Zynerba Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Zynerba Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2023.
  • Zynerba Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2023 was 24 %, a 60.8% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 24 +9.07 +60.8% Jun 30, 2023
Q1 2023 19.6 +5.99 +43.9% Mar 31, 2023
Q4 2022 17.1 +3.55 +26.2% Dec 31, 2022
Q3 2022 15.8 +0.64 +4.23% Sep 30, 2022
Q2 2022 14.9 -0.59 -3.81% Jun 30, 2022
Q1 2022 13.7 -3.4 -19.9% Mar 31, 2022
Q4 2021 13.6 -4.33 -24.2% Dec 31, 2021
Q3 2021 15.2 -1.15 -7.06% Sep 30, 2021
Q2 2021 15.5 +0.61 +4.1% Jun 30, 2021
Q1 2021 17.1 +3.68 +27.5% Mar 31, 2021
Q4 2020 17.9 +5.5 +44.4% Dec 31, 2020
Q3 2020 16.3 +3.97 +32.2% Sep 30, 2020
Q2 2020 14.9 +1.67 +12.6% Jun 30, 2020
Q1 2020 13.4 -3.4 -20.3% Mar 31, 2020
Q4 2019 12.4 -6.76 -35.3% Dec 31, 2019
Q3 2019 12.3 -5.78 -31.9% Sep 30, 2019
Q2 2019 13.2 Jun 30, 2019
Q1 2019 16.8 Mar 31, 2019
Q4 2018 19.2 Dec 31, 2018
Q3 2018 18.1 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.